BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2018
Price : $35 *
At a glance
- Drugs Betrixaban (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- Acronyms BRAVO
- Sponsors Portola Pharmaceuticals
- 29 Nov 2018 Status changed from not yet recruiting to suspended.
- 20 Sep 2018 Planned initiation date changed from 1 Aug 2018 to 1 Sep 2018.
- 10 Aug 2018 New trial record